SCHEDULE: Addex Therapeutics CEO Discloses Share Ownership Update

Timothy Mark Dyer, CEO of Addex Therapeutics Ltd, has filed an amendment to Schedule 13D detailing his beneficial ownership of 19,165,714 shares, representing 9.01% of the company, following a reduction in option strike prices.

Summary

• Timothy Mark Dyer, CEO and Board member of Addex Therapeutics Ltd, has filed an amendment (Amendment No. 10) to his Schedule 13D.
• The filing reports his beneficial ownership of 19,165,714 ordinary shares, constituting 9.01% of the company's outstanding shares as of August 26, 2026.
• This ownership includes 16,848,979 ordinary shares and 2,316,735 shares issuable upon exercise of options exercisable within 60 days of September 2, 2026.
• A key event noted is the reduction of the strike price for certain options to CHF0.026 per share, effective September 2, 2026.
• The shares were acquired through various means including founding shares, private placements, compensation for services as CEO, and exercise of stock options.
• Dyer confirms he has no present plans for extraordinary corporate transactions, asset sales, or changes to management or capitalization, but reserves the right to change plans.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting an update on beneficial ownership and share options with a recent strike price reduction, but without significant new strategic information.

Positives

• The CEO's significant beneficial ownership (9.01%) indicates strong alignment with shareholder interests.
• The reduction in strike prices for options may improve the potential value realization for the CEO and potentially other option holders.
• The filing confirms the CEO's continued commitment to the company through various share acquisition methods.

Negatives

• The filing does not disclose any new strategic initiatives or significant operational updates, focusing primarily on ownership details.
• A portion of the shares (1,053,061) acquired through options exercised on November 27, 2023, are not freely tradable as of September 2, 2026, indicating potential liquidity constraints for a subset of these shares.

Risks

• The filing notes that 1,053,061 shares acquired via options exercised on November 27, 2023, are not freely tradable as of September 2, 2026, which could impact liquidity for these specific shares.
• While the CEO states no current plans for significant corporate changes, the reservation of the right to change plans introduces an element of uncertainty regarding future strategic direction.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, it notes that the Reporting Person reserves the right to change plans at any time based on ongoing evaluation of business objectives, financial condition, prospects, share price, and market conditions.

Management Comments

• The Reporting Person does not have any present plans which relate to or would result in: acquisition or disposition of securities, extraordinary corporate transactions, sale of material assets, changes in Board of Directors or management, material changes in capitalization or dividend policy, or other material changes in business or corporate structure.
• The Reporting Person reserves the right to change its plans at any time, as it deems appropriate, in light of its ongoing evaluation of (i) its business and liquidity objectives; (ii) the Issuer's financial condition, business, operations, competitive position, prospects and/or Share price; (iii) industry, economic and/or securities markets conditions; (iv) alternative investment opportunities; and (v) other relevant factors.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are common for significant beneficial owners and often reflect changes in holdings or strategic intentions. This particular filing updates ownership details for the CEO of Addex Therapeutics, a biopharmaceutical company, following adjustments to option terms.

Stakeholder Impact

• Shareholders: The CEO's significant ownership and the update on option strike prices may be viewed positively, indicating alignment. However, the lack of new strategic information limits immediate impact.
• Employees: The CEO's compensation structure, including stock options, is detailed, reflecting a component of employee incentive and retention.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The Reporting Person will continue to evaluate the Issuer's performance, market conditions, and alternative investment opportunities, reserving the right to adjust plans regarding their holdings.
• The company's ordinary shares are listed on the SIX Swiss Exchange and the Nasdaq Capital Market.

Key Dates

Keywords

Addex Therapeutics, Schedule 13D, Beneficial Ownership, CEO, Stock Options, Shareholder, Option Strike Price, Corporate Governance